Prostate Cancer Market is Expected to Reach $19,568.7 Million by 2026

ABOUT THIS REPORT

OVERVIEW

Prostate Cancer Market is valued at USD XX million in 2019 and is expected to reach USD 19,568.7 million by the end of 2026.

Bizlytik analysts forecast the global Prostate Cancer market to grow at a CAGR of 7.6% during the forecast period, according to their latest market research report.

Prostate cancer happens in the prostate gland, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. The prostate cancer types include adenocarcinomas, Small cell carcinomas, Neuroendocrine tumors, Transitional cell carcinomas, and Sarcomas. Treatment for prostate cancer includes Surgery, Radiation therapy, Focal therapies, Testosterone suppression therapy and androgen axis inhibitors, Chemotherapy, and Immunotherapy.

According to the American Cancer Society, it is estimated that in 2020 there will be 191,930 new cases of prostate cancer and 33,330 deaths from prostate cancer in the United States. According to the Cancer Research UK, there are over 48,500 new prostate cancer cases in the UK every year. Prostate cancer accounts for 26% of all new cancer cases in males in the UK. According to the Australian Institute of Health and Welfare, in 2019, there were 19,508 new cases of prostate cancer and 3,306 deaths from prostate cancer in Australia. According to the Pan-American Health Organization, the incidence rate of prostate cancer and deaths from this disease are expected to double in Brazil by 2030.

Medication (Hormone therapy, Chemotherapy, Immunotherapy), Radiation Therapy (External-beam radiation therapy, Brachytherapy), and Focal Therapy (Cryosurgery, High-intensity focused ultrasound (HIFU)) are covered in the Type segment of the market scope, and the End user segment is divided into Hospitals, Ambulatory Surgical Centre’s, Others. The report covers value of the global market by Type and End user.

The market value of Medication was USD XX Million in 2019, and it is expected to reach USD XX Million by 2026, growing at a CAGR of 8.2% during 2020-2026. The regulatory approval for manufacturing and commercializing prostate cancer medication would propel the growth of the segment.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global Prostate Cancer Value figures. While North America is further categorized into enhancing United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.
North America Prostate Cancer market was USD XX Million in 2019, and it is predicted to reach USD XX Million by 2026, growing at a CAGR of 8.8% during the forecast period. The increasing prevalence of prostate cancer, the partnership between companies to develop products, commercialization of new product, regulatory approval for prostate cancer products and government initiative and funding for prostate cancer research are some of the factors that would improve the growth prospects of the market.

Major players operating in the Prostate Cancer industry include Johnson & Johnson, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Ipsen SA, Abbvie Inc., Dendreon Pharmaceuticals LLC, Tolmar Inc.

The commercialization of new product, regulatory approval for prostate cancer products, government funding for prostate cancer research, and partnership between companies to conduct studies on prostate cancer, are some of the strategies adopted by the companies.